Viking Therapeutics, Inc. (VKTX): Price and Financial Metrics

Viking Therapeutics, Inc. (VKTX): $4.01

-0.08 (-1.96%)

POWR Rating

Component Grades













VKTX Stock Price Chart Interactive Chart >

Price chart for VKTX

VKTX Price/Volume Stats

Current price $4.01 52-week high $5.65
Prev. close $4.09 52-week low $2.02
Day low $3.98 Volume 161,700
Day high $4.07 Avg. volume 969,763
50-day MA $3.60 Dividend yield N/A
200-day MA $3.14 Market Cap 307.52M

Viking Therapeutics, Inc. (VKTX) Company Bio

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures. The company is also developing VK2809, an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in a Phase II clinical trial for the treatment of patients with hypercholesterolemia and fatty liver disease; and in a Phase I clinical trial to treat patients who suffer from glycogen storage disease type Ia. In addition, it is developing VK0214 for X-linked adrenoleukodystrophy, which is in pre-clinical stage. Viking Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.

VKTX Latest News Stream

Event/Time News Detail
Loading, please wait...

VKTX Latest Social Stream

Loading social stream, please wait...

View Full VKTX Social Stream

Latest VKTX News From Around the Web

Below are the latest news stories about VIKING THERAPEUTICS INC that investors may wish to consider to help them evaluate VKTX as an investment opportunity.

My 3 Top Biotech Stock Picks for 2023

Biotech stocks, on balance, had a year to forget in 2022. An unsavory mix of profit-taking, clinical setbacks, a stricter Food and Drug Administration (FDA), geopolitcal unrest, rising interest rates, and good old fashioned risk aversion sent key indicators like the SPDR S&P Biotech ETF spiraling downward this year. Hammering this point home, the SPDR S&P Biotech ETF plummeted by a staggering 53% -- from its prior three-year high -- through the first 11 months of 2022.

Yahoo | November 22, 2022

A Viking Therapeutics, Inc. (NASDAQ:VKTX) insider increased their holdings by 68% last year

Insiders were net buyers of Viking Therapeutics, Inc.'s ( NASDAQ:VKTX ) stock during the past year. That is, insiders...

Yahoo | November 16, 2022

Viking Therapeutics to Present at Stifel 2022 Healthcare Conference

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of the Stifel 2022 Healthcare Conference. The conference will take place November 15-16, 2022, in New York City.

Yahoo | November 8, 2022

Analysts Are Bullish on Top Healthcare Stocks: Viking Therapeutics (VKTX), Sanofi (SNYNF)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viking Therapeutics (VKTX – Research Report) and Sanofi (SNYNF – Research Report) with bullish sentiments. Viking Therapeutics (VKTX) Maxim Group analyst Naz Rahman maintained a Buy rating on Viking Therapeutics yesterday and set a price target of $10.00. The company's shares closed last Thursday at $4.03. According to TipRanks.

Catie Powers on TipRanks | October 28, 2022

Viking Therapeutics, Inc. (VKTX) Q3 2022 Earnings Call Transcript

Viking Therapeutics, Inc. (VKTX)

Q3 2022 Earnings Conference Call

October 26, 2022 04:30 PM ET

Company Participants

Stephanie Diaz - Manager, Investor Relations

Brian Lian - President & Chief Executive Officer

Greg Zante - Chief Financial Officer

Conference Call Participants

Steve Seedhouse - Raymond James

Joon Lee - Truist

Andy Hsieh - William Blair

Thomas Smith - SVB Securities

Yale Jen - Laidlaw

Scott Henry - ROTH Capital

Justin Zelin - BTIG

Naz Rahman - Maxim Group



Welcome to the Viking Therapeutics' 2022 Third Quarter Financial Results Conference Call. At this time, all participan...

SA Transcripts on Seeking Alpha | October 27, 2022

Read More 'VKTX' Stories Here

VKTX Price Returns

1-mo -3.61%
3-mo 21.15%
6-mo 80.63%
1-year -25.46%
3-year -46.14%
5-year 42.20%
YTD -12.83%
2021 -18.29%
2020 -29.80%
2019 4.84%
2018 88.42%
2017 241.18%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.715 seconds.